Mtz Clinical Research Powered By Pratia

Warsaw 95 trials 45 recruiting

95 Registered trials

45 Currently recruiting

Organisation

Mtz Clinical Research Powered By Pratia

Location

Warsaw, Poland

Identifier

ORG-100037261

Address

Ul. Gładka 22, 02-172, Poland

Departments

-
#40699: N/A
Badania Kliniczne
Cardiology
Clinical Unit
Dermatology
Gynaecology
Hematology
Mtz Clinical Research Powered By Pratia
MTZ Clinical Research powered by Pratia, Warszawa
n/a
N/D
NA
NA/ND
ND
Neurology
Oncology
Phase I unit
Private Practice
Psychiatry
Site unit

Clinical trials at this site (95)

Search interface

Phase Ia/Ib Study of UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies Pending

2023-510484-35-00 B-cell malignancies 1
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Pending

2024-516805-22-00 Major Depressive Disorder 5
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures Pending

2025-520587-18-00 Focal Onset Seizures 4
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD) Pending

2025-520631-17-00 Huntington’s Disease Gene Expansion Carriers 1
Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy parti… Pending

2025-522468-34-00 Androgenetic alopecia 3
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911 Pending

2025-523355-59-00 Immune Thrombocytopenia, Hematopoietic Syndrome of Acut 2
A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending

2025-524640-35-00 Ulcerative colitis (Inflammatory Bowel Disease) 4
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting

2025-523815-12-00 Relapsed or Refractory Multiple Myeloma 5 2026-07-06
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without … Recruiting

2024-518858-17-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 4 2026-05-22
A study on the immune response and safety of an investigational chickenpox vaccine and a marketed measles, mumps and rubella vaccine when ad… Recruiting

2024-518840-18-00 Varicella 5 2025-12-10
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibit… Recruiting

2025-521088-10-00 Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia 4 2025-10-23
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting

2024-512126-29-00 Generalized Myasthenia Gravis 5 2025-02-25
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Generalized Myasthenia Gravis 5 2024-11-27
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immun… Recruiting

2023-508661-33-00 Rheumatoid Arthritis 1 2024-05-29
A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Recruiting

2025-523544-12-00 Myelodysplastic neoplasms/syndromes (MDS) 5 2026-06-02
A Phase 1/2 Study of Pumitamig alone or in Combination with Ipilimumab in First-Line HCC Recruiting

2025-523602-33-00 Advanced or unresectable Hepatocellular Carcinoma (HCC) 9 2026-05-13
SAFEGUARD (SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes) Study Recruiting

2025-521560-36-00 Type 1 Diabetes 4 2026-04-22
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24